Abstract
Based on their mechanism of action, anti-tumor drugs that target the cell cycle can be generally divided into three categories, namely, blocking DNA synthesis, causing DNA damage, and disrupting mitotic processes. In terms of mitotic inhibitors, most compounds used in the clinic impair the normal function of mitotic spindles by targeting tubulins, basic building blocks of microtubules. In vivo, these compounds often exhibit significant side effects, thus limiting their efficacy. Mitotic processes are under tight control through surveillance mechanisms commonly termed checkpoints. Defects in the regulation of these checkpoints often result in genomic instability, which predisposes the cell to malignant transformation. As cancer is the consequence of uncontrolled cell division, great efforts have been devoted to discover drugs that target mitosis, thereby halting cell division and inducing mitotic catastrophe with minimal cytotoxicity to nondividing or normally dividing cells. This review primarily focuses on mitotic proteins that have been explored as new targets for anti-cancer drug development during the past decade.
Keywords: Mitosis, microtubules, kinesins, Aurora kinases, Polo-like kinases, small compounds, cell cycle checkpoint, mitotic catastrophe
Mini-Reviews in Medicinal Chemistry
Title: Advances in Mitotic Inhibitors for Cancer Treatment
Volume: 6 Issue: 8
Author(s): Ning Jiang, Xiaoxing Wang, Yali Yang and Wei Dai
Affiliation:
Keywords: Mitosis, microtubules, kinesins, Aurora kinases, Polo-like kinases, small compounds, cell cycle checkpoint, mitotic catastrophe
Abstract: Based on their mechanism of action, anti-tumor drugs that target the cell cycle can be generally divided into three categories, namely, blocking DNA synthesis, causing DNA damage, and disrupting mitotic processes. In terms of mitotic inhibitors, most compounds used in the clinic impair the normal function of mitotic spindles by targeting tubulins, basic building blocks of microtubules. In vivo, these compounds often exhibit significant side effects, thus limiting their efficacy. Mitotic processes are under tight control through surveillance mechanisms commonly termed checkpoints. Defects in the regulation of these checkpoints often result in genomic instability, which predisposes the cell to malignant transformation. As cancer is the consequence of uncontrolled cell division, great efforts have been devoted to discover drugs that target mitosis, thereby halting cell division and inducing mitotic catastrophe with minimal cytotoxicity to nondividing or normally dividing cells. This review primarily focuses on mitotic proteins that have been explored as new targets for anti-cancer drug development during the past decade.
Export Options
About this article
Cite this article as:
Jiang Ning, Wang Xiaoxing, Yang Yali and Dai Wei, Advances in Mitotic Inhibitors for Cancer Treatment, Mini-Reviews in Medicinal Chemistry 2006; 6 (8) . https://dx.doi.org/10.2174/138955706777934955
DOI https://dx.doi.org/10.2174/138955706777934955 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Strategies for Development of Antimalarials Based on Encapsulated Porphyrin Derivatives
Mini-Reviews in Medicinal Chemistry Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides
Current Drug Targets Recent Patents, Formulation and Characterization of Nanoliposomes
Recent Patents on Drug Delivery & Formulation Anti-miRNA-23a Oligonucleotide Suppresses Glioma Cells Growth by Targeting Apoptotic Protease Activating Factor-1
Current Pharmaceutical Design Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Current Gene Therapy Screening Novel SAHA Derivatives as Anti-lung Carcinoma Agents: Synthesis, Biological Evaluation, Docking Studies and Further Mechanism Research between Apoptosis and Autophagyetween Apoptosis and Autophagy
Anti-Cancer Agents in Medicinal Chemistry Molecular Markers of Tumor Progression in Melanoma
Current Genomics The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features
Current Drug Targets Trends in the Treatment of Hepatocellular Carcinoma
Current Drug Therapy Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Interplay of Drug-Metabolizing Enzymes and Transporters in Drug Absorption and Disposition
Current Drug Metabolism The Design of Amphiphilic Polymeric Micelles of Curcumin for Cancer Management
Current Medicinal Chemistry Recent Progress in the Functionalization of Benzo-γ-Pyrones via Transition- Metal Catalyzed Cross-Coupling Reactions
Mini-Reviews in Organic Chemistry Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy